Bioequivalence evaluation of 320 mg gemifloxacin tablets in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 11, 2007, Pages 617-622

  Al Mohizea, A M ^a   Kadi, A A ^a   Al Bekairi, A M ^a   Al Balla, S A ^b   Al Yamani, M J ^a   Al Khamis, K I ^a   Niazy, E M ^a   El Sayed, Y M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Bioavailability; Bioequivalence; Comparative; Factive; Gemifloxacin; Healthy volunteers

Indexed keywords

GEMIFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 35748932070     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45617     Document Type: Article

References (15)

1. Allen A. Bygate E, Teillol-Foo M, Oliver SD, Johnson MR, Ward C. Pharmacokinetics and tolerability of gemifloxacin after administration of single oral doses to healthy volunteers (Abstract P440). J Antimicrob Chemother. 1999; 44 (Suppl A): 137.
2. Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents. 2000; 16: 45-50.
3. Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob Agents Chemother. 1997; 41: 204-211.
4. Critchley IA, Broskey J, Coleman K. SB-265805 (LB-20304a): In vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophages. San Diego, CA: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (Poster F-100); 1998. p. 257.
5. EMEA. Note for guidance on the investigation of bioavailability and bioequivalence. The European Agency for the Evaluation of Medicinal Products. London 2001; p. 1-18.
6. FDA. Guidance for Industry: bioanalytical method validation. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research: Rockville; 2001. p. 1-22.
7. Felmingham D, Robbins MJ, Dencer C, Salman H, Mathias I, Ridgway GL. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp. (Abstract P408). J Antimicrob Chemother. 1999; 44 (Suppl A): 131.
8. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-78.
9. Hauschke D, Steinijans VW, Diletti E, Burk M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992; 20: 557-561.
10. Hardy D, Amsterdam D, Mandell L, Rotstein C. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. Antimicrob Agents Chemother. 2000; 44: 802-805.
11. Hohl AF, Frei R, Pünter V et al. International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin Microbiol Infect. 1998; 4: 280-284.
12. Moore T, Niconovich N, Coleman K. SB-265805 (LB20304a): In vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. San Diego, CA: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (Poster F-098); 1998. p. 257.
13. Naber KG, Hollauer K, Kirchbauer D, Witte W. In vitro activity of SB-265805 versus gatifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens. Clin Microbiol Infect. 1999; 5 (Suppl 3): 144.
14. Oh JI, Paek KS, Ahn MJ et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agenths Chemother. 1996; 40: 1564-1568.
15. Schuirmannn DJ. A comparison of the 2 one-sided test procedures and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.